Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE7.0200
- TODAY'S CHANGE (%)0.0800 (1.1527%)
- Bid / Lots6.6000/ 1
- Ask / Lots7.0600/ 1
- Open / Previous Close6.9000 / 6.9400
- Day Range
- 52 Week Range
- Volume76,161
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 3815 | 6.9 |
| 09:34 ET | 100 | 6.995 |
| 09:39 ET | 664 | 7.035 |
| 09:50 ET | 100 | 6.95 |
| 09:54 ET | 500 | 7.08 |
| 09:56 ET | 400 | 7.11 |
| 09:59 ET | 100 | 7.1 |
| 10:08 ET | 100 | 7.1 |
| 10:10 ET | 726 | 7.06 |
| 10:12 ET | 200 | 7.06 |
| 10:14 ET | 100 | 7.05 |
| 10:15 ET | 100 | 7.06 |
| 10:21 ET | 100 | 7.05 |
| 10:24 ET | 100 | 7.05 |
| 10:30 ET | 200 | 7.05 |
| 10:48 ET | 700 | 7.04 |
| 10:50 ET | 364 | 7.045 |
| 10:51 ET | 300 | 7.06 |
| 10:57 ET | 700 | 7.05 |
| 11:08 ET | 100 | 7.06 |
| 11:13 ET | 430 | 7.05 |
| 11:20 ET | 100 | 7.055 |
| 11:24 ET | 600 | 7.06 |
| 11:26 ET | 200 | 7.06 |
| 11:27 ET | 200 | 7.05 |
| 11:29 ET | 100 | 7.05 |
| 11:31 ET | 200 | 7.05 |
| 11:33 ET | 1995 | 7.05 |
| 11:36 ET | 498 | 7.04 |
| 11:42 ET | 281 | 7.005 |
| 11:44 ET | 100 | 7 |
| 11:51 ET | 100 | 7.01 |
| 11:56 ET | 100 | 7.05 |
| 12:02 ET | 200 | 7.025 |
| 12:07 ET | 600 | 7.04 |
| 12:30 ET | 500 | 7.05 |
| 12:32 ET | 300 | 7.06 |
| 12:38 ET | 100 | 7.02 |
| 12:57 ET | 2300 | 7.03 |
| 12:59 ET | 200 | 7.03 |
| 01:01 ET | 500 | 7.03 |
| 01:03 ET | 664 | 7.015 |
| 01:06 ET | 473 | 7.01 |
| 01:17 ET | 100 | 7.005 |
| 01:19 ET | 100 | 7.015 |
| 01:30 ET | 100 | 6.99 |
| 01:32 ET | 300 | 7 |
| 01:33 ET | 900 | 6.995 |
| 01:48 ET | 100 | 7.01 |
| 01:51 ET | 100 | 7.005 |
| 01:57 ET | 3289 | 7.01 |
| 02:09 ET | 100 | 7.02 |
| 02:11 ET | 120 | 7.03 |
| 02:13 ET | 532 | 6.987 |
| 02:15 ET | 200 | 6.97 |
| 02:18 ET | 100 | 6.975 |
| 02:22 ET | 964 | 6.98 |
| 02:24 ET | 100 | 6.96 |
| 02:31 ET | 200 | 6.96 |
| 02:42 ET | 300 | 6.97 |
| 02:44 ET | 100 | 6.99 |
| 02:56 ET | 100 | 7 |
| 03:02 ET | 964 | 6.975 |
| 03:05 ET | 1200 | 7.01 |
| 03:14 ET | 3144 | 6.98 |
| 03:21 ET | 200 | 7 |
| 03:23 ET | 519 | 7.01 |
| 03:34 ET | 100 | 7.02 |
| 03:36 ET | 100 | 7.02 |
| 03:39 ET | 1963 | 7.02 |
| 03:41 ET | 289 | 7.02 |
| 03:48 ET | 144 | 7.02 |
| 03:50 ET | 2849 | 7.035 |
| 03:52 ET | 400 | 7.025 |
| 03:54 ET | 126 | 7.0201 |
| 03:56 ET | 100 | 7.03 |
| 03:57 ET | 2455 | 7.03 |
| 03:59 ET | 13770 | 7.02 |
Sep 5, 2024
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 7:30AM ET on Thursday Sep 05, 2024 by Dow Jones
7:30AM ET on Thursday Sep 05, 2024 by Dow Jones
Sep 4, 2024
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences, from 4:05PM ET on Wednesday Sep 04, 2024 by Dow Jones
4:05PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 150.4M | -0.9x | --- |
Century Therapeutics Inc | 135.2M | -0.8x | --- |
Prelude Therapeutics Inc | 152.4M | -1.1x | --- |
Outlook Therapeutics Inc | 153.1M | -0.7x | --- |
Actuate Therapeutics Inc | 153.1M | -5.1x | --- |
aTyr Pharma Inc | 144.0M | -1.9x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Medical Officer
- Rabia Ozden
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $150.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-7.99 |
Book Value | $8.23 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
